

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 598 419 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
23.11.2005 Bulletin 2005/47

(21) Application number: 04715540.3

(22) Date of filing: 27.02.2004

(51) Int Cl.7: **C12N 15/00**, C07K 16/32,
C12N 5/00, C12P 21/08,
A61K 39/395, A61K 9/127,
A61P 35/00, G01N 33/574

(86) International application number:
PCT/JP2004/002402

(87) International publication number:
WO 2004/076658 (10.09.2004 Gazette 2004/37)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: 28.02.2003 JP 2003054670
09.07.2003 JP 2003194643

(71) Applicants:
• **Mitsubishi Pharma Corporation**
Osaka-shi, Osaka 541-0046 (JP)
• **Keio University**
Tokyo 108-0073 (JP)

(72) Inventors:
• **HOSOKAWA, Saiko,**
c/o Mitsubishi Pharma Corporation
Tokyo 1038405 (JP)
• **AOKI, Masahiko, School Of Medicine, Keio Univ.**
Tokyo 1608582 (JP)

• **HIRAKAWA, Yoko,**
c/o Mitsubishi Pharma Corporation
Tokyo 1038405 (JP)
• **ITAMI, Selma,**
c/o Mitsubishi Pharma Corporation
Tokyo 1038405 (JP)
• **UMEKI, Hiroe,**
c/o Mitsubishi Pharma Corporation
Tokyo 1038405 (JP)
• **SAIKAWA, Yoshiro,**
School Of Medicine, Keio Univ.
Tokyo 1608582 (JP)
• **KUMAI, Koichiro, School Of Medicine, Keio Univ.**
Tokyo 1608582 (JP)
• **FUKUDA, Kazumasa,**
School Of Medicine, Keio Univ.
Tokyo 1608582 (JP)

(74) Representative: **von Kreisler Selting Werner**
Patentanwälte
P.O. Box 10 22 41
50462 Köln (DE)

(54) **MONOCLONAL ANTIBODY, GENE ENCODING THE SAME, HYBRIDOMA, MEDICINAL COMPOSITION AND DIAGNOSTIC REAGENT**

(57) A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by using the antibody alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein. More specifically, an anti-cancer drug is obtained by using an antibody, in which variable region of its heavy chain comprises the amino acid sequence of SEQ ID NO: 115 and variable region of the light chain comprises the amino acid sequence of SEQ ID NO: 117, alone or anchoring the antibody on the surface of a liposome containing a

toxin or an anti-cancer drug encapsulated therein.




Fig. 2

EP 1 598 419 A1